Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,094 total articles
Magnetar Financial LLC, a roughly 10% holder of Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR), sold a total of 23,088 shares of Wheeler common stock between April 1 and April 6, 2026, for approximately $21,460. The trades came in three blocks at weighted average prices from $0.9234 to $0.9466 per share. Wheeler continues to adjust its c…
Lipocine Inc. (NASDAQ:LPCN) Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of company stock on April 6, 2026 at $2.03 per share, totaling $50,749. The transaction occurs as the share price trades close to a 52-week low of $1.81 after a 74% decline over the prior week. Separately, Lipocine disclosed that its postpartum depression dr…
Arve Hanstveit, a director at Energy Recovery, Inc. (NASDAQ: ERII), sold 165,292 shares on April 2, 2026, for roughly $1.67 million at $10.14 per share. The disposition was executed by a broker without Hanstveit's instruction to satisfy a margin call on shares pledged as collateral. The transaction comes as Energy Recovery reported fourth-quarter 2…
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (NASDAQ: AIP), sold 3,649 shares of common stock on April 2, 2026, in transactions executed at $17.6528 per share, totaling $64,415. The disposals were carried out to satisfy tax obligations tied to the release of restricted stock units and were not described as discretionary trade…
Planet Labs PBC President and CFO Ashley F. Johnson sold 200,000 Class A shares on April 2, 2026, for roughly $7,020,218, and on April 6, 2026 moved 525,708 shares into The Johnson Joint Revocable Trust. The company also reported stronger-than-expected fourth-quarter fiscal 2026 results, received mixed analyst target revisions, announced a Pelican …
Lightwave Logic director Thomas M. Connelly Jr. sold 9,000 shares of common stock on April 6, 2026, for $8.52 per share, yielding $76,680. The sale, disclosed on a Form 4, was made to meet tax-withholding obligations tied to restricted stock unit vestings on March 31, 2026. The move comes as Lightwave Logic's stock has climbed 786% over the past ye…
Charles Janac, president and chief executive of Arteris, Inc. (NASDAQ:AIP), sold a combined $375,438 of company stock in two transactions on April 2 and April 6. The April 2 sales covered tax obligations from restricted stock units, while the April 6 sale occurred under a 10b5-1 plan adopted March 5, 2025. The moves coincide with a steep share-pric…
Arteris, Inc. CFO Nicholas B. Hawkins disposed of 5,870 shares on April 2, 2026, in multiple transactions disclosed on a Form 4, raising $85,969. The sales were reported as tax-covering actions tied to the vesting of restricted stock units. Arteris recently posted better-than-expected fourth-quarter 2025 results, while InvestingPro flags the stock …
Arteris, Inc. (NASDAQ: AIP) Chief Operating Officer Laurent R. Moll sold a combined $127,182 of company shares on April 2 and April 6, with the April 2 transactions intended to cover tax liabilities tied to restricted stock units and the April 6 sale conducted under a prearranged 10b5-1 plan. The moves come as Arteris shares trade near a 52-week hi…
Iridium Communications Inc. (NASDAQ: IRDM) reported two insider sales by Timothy Kapalka, Chief Administrative Officer of Iridium Satellite LLC, totaling 5,833 shares and $184,909 in proceeds. The sales occurred on April 2 and April 6 at $31.00 and $33.00 per share, respectively. The disclosures arrive while IRDM trades near its 52-week high follow…
Beam Therapeutics Chief Medical Officer Amy Simon sold 6,700 shares on April 1, 2026, in an automated transaction to satisfy tax withholding tied to vesting restricted stock units. The sale, executed under a Rule 10b5-1 trading plan adopted May 19, 2023, totaled $164,686. Beam shares trade near $24.23 amid recent clinical data releases that have le…
Altimmune director John Gill purchased 9,200 shares of company stock on April 6, 2026, paying between $3.4050 and $3.4080 per share for a total of $31,349. The transaction occurred while the shares have climbed more than 15% in the prior week. The company recently posted fourth-quarter 2025 results that missed expectations on both EPS and revenue, …
Beam Therapeutics Inc. CEO John M. Evans sold 30,078 shares on April 1, 2026, generating about $739,317 to satisfy tax-withholding tied to the vesting of restricted stock units. The sale, executed under a Rule 10b5-1 plan adopted in May 2023, leaves Evans with direct and indirect holdings exceeding 1.15 million shares. Separately, Beam published Ph…
Lands’ End CFO and Treasurer Bernard Louis McCracken III sold 3,362 shares of common stock on April 1, 2026, at $45 per share, totaling $151,290, while exercising and receiving additional shares at no cost. The transactions occurred as the stock trades well below that sale price and after the company reported a fourth-quarter earnings and revenue m…
UWM Holdings Corp saw combined insider sales of 2,001,148 Class A shares by CEO Mat Ishbia and 10%-owner SFS Holding Corp for about $7.4 million across two transactions in early April 2026. The trades coincide with volatile share performance, dividend yield above 10%, recent quarterly revenue beats and ongoing merger-related developments involving …
DoorDash director Stanley Tang sold 23,125 shares of Class A stock on April 2, 2026, for $150 per share, totaling $3,468,750. The sale, carried out under a Rule 10b5-1 plan established December 3, 2025, leaves Tang with a mix of direct and indirect holdings across Class A and Class B shares. The company also announced a national delivery partnershi…
Entities tied to GEC Partners III LP sold a combined $24,774,750 of Flowco Holdings Inc. (NASDAQ: FLOC) Class A common stock on March 26, 2026, at $21.175 per share, while simultaneously acquiring equivalent amounts through conversion of LLC interests. The stock trades at $20.69 with a $1.86 billion market capitalization, and InvestingPro's Fair Va…
Bethany Cavanagh, Beam Therapeutics' SVP of Finance and Treasurer, sold 3,242 shares on April 1, 2026, under a Rule 10b5-1 plan to meet tax withholding obligations tied to RSU vesting. The transaction totaled $79,688. Beam has recently disclosed clinical data from its BEACON sickle cell program and BEAM-302 alpha-1 antitrypsin deficiency study, pro…
Christine Bellon, Chief Legal Officer of Beam Therapeutics (NASDAQ: BEAM), sold 5,956 shares on April 1, 2026, in an automatic transaction to meet tax withholding obligations tied to vested restricted stock units. The sale, carried out under a Rule 10b5-1 plan adopted in May 2023, generated $146,398 at $24.58 per share. Beam has recently disclosed …
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 Class A shares on April 6, 2026, for roughly $56,013 under a 10b5-1 plan. The transaction leaves Lorrain with 147,712 directly held shares and 6,842 indirectly held through his spouse. The stock trades at $13.44, Company market capitalization is $502 million and the balanc…
Giuseppe Ciaramella, president of Beam Therapeutics (BEAM), sold 11,810 shares on April 1, 2026, for $24.58 per share, netting roughly $290,289. The sale was an automatic disposition to satisfy tax withholding tied to restricted stock unit vesting under a Rule 10b5-1 plan adopted in May 2023. The company’s shares have risen 59% over the past year b…
Guidewire Software CEO Michael George Rosenbaum sold 1,200 shares on April 6, 2026 under a pre-arranged 10b5-1 plan, generating roughly $181,367. The transaction follows a quarter of outperformance and raised fiscal 2026 guidance even as the stock has fallen materially in recent months and some analysts trimmed price targets amid valuation concerns…
Entities affiliated with GEC Advisors LLC sold a total of 7,800,000 shares of Flowco Holdings Inc. (FLOC) on March 26, 2026, at $21.175 per share, generating $165,165,000. The transactions coincided with conversions of LLC Interests into Class A common stock by the same entities and follow a planned secondary offering in which affiliates marketed 7…
A 10% owner of Clene Inc. sold roughly $120,000 of stock on April 2, 2026, while the company announced regulatory and financing milestones tied to its investigational ALS therapy CNM-Au8. The sale leaves the insider with just over 401,000 shares held through SymBiosis II, LLC. Separately, Clene received an in-person Type C meeting with the FDA to r…
Elizabeth Leykum, a member of Lands' End Inc.'s board, sold 935 shares on April 1, 2026, in a transaction tied to a tender offer, generating $42,075. The sale occurred at $45.00 per share, well above the company's prevailing market price of $10.90. Lands' End reported fiscal 2025 fourth-quarter results that missed analyst projections on both earnin…
